[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].
Gan To Kagaku Ryoho
; 50(2): 239-241, 2023 Feb.
Article
em Ja
| MEDLINE
| ID: mdl-36807184
ABSTRACT
BACKGROUND:
Since a randomized phase â ¢ trial conducted in the UK in 2009 showed the superiority of gemcitabine (GEM)plus cisplatin(CDDP)combination therapy over GEM monotherapy, GEM plus CDDP combination therapy has been first-line chemotherapy for unresectable biliary tract cancer.METHODS:
GEM plus CDDP combination therapy was administered to 29 patients with unresectable biliary tract cancer from 2016 to 2021.RESULTS:
The mean age was 71.9 years, male/ female 19/10. The target of chemotherapy was below, local progression was 3 cases, first distant metastasis 7 cases, metastatic recurrence 19 cases. The type of cancer was below, intrahepatic bile duct carcinoma was 8 cases, hepatic hilar bile duct carcinoma 6 cases, gallbladder carcinoma 5 cases, cystic duct carcinoma 1 case, distal bile duct carcinoma 6 cases, and papilla Vater's cancer 3 cases. The dosing period was 23.1 weeks(range 2-52 weeks). The relative dose intensities of GEM and CDDP were 73.7% and 75.1%. The adverse events were below, the hematological toxicities of Grade 3 or higher were neutropenia(65.5%), leukopenia(3.4%), and thrombocytopenia(10.3%). Non-hematological toxicities of Grade 2 or higher were fatigue(13.7%)and skin rash(6.9%). There was no interstitial pneumonia. The disease control rate was 66.7 %(complete response, n=0; partial response, n=6; stable disease, n=10; progressive disease, n=8).CONCLUSION:
GEM plus CDDP combination therapy was safe to perform and was an effective treatment for unresectable biliary tract cancer.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Trombocitopenia
/
Neoplasias dos Ductos Biliares
/
Neoplasias do Sistema Biliar
/
Colangiocarcinoma
/
Neoplasias da Vesícula Biliar
/
Neoplasias Gastrointestinais
/
Anemia
/
Neutropenia
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
Ja
Ano de publicação:
2023